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4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid (4-guanidino-Neu5Ac2en) specifically inhibits the influenza
virus neuraminidase (NA) through interaction of the guanidino group with conserved Glu 119 and Glu 227 residues in the
substrate binding pocket of the enzyme. To understand the mechanism by which influenza viruses become resistant to 4-
guanidino-Neu5Ac2en, we investigated mutations at amino acid residues 119 and 227 in the influenza virus NA for their
effects on this compound and on NA activity. The NA gene was cloned from the NWS-G70c virus, and mutations were
introduced at the codon for amino acid residue 119 or 227. All of the 13 mutants containing a change at residue 119 were
transported to the cell surface, although their expression levels ranged from 68.2 to 91.3% of wild type. Mutant NAs that
retained at least 20% of the wild-type enzymatic activity were tested for their sensitivity to 4-guanidino-Neu5Ac2en and
found to be sevenfold less sensitive to this compound than was the wild-type NA. By contrast, only 6 of 13 mutants defined
by modifications at residue 227 were transported to the cell surface, and those NAs lacked substantial enzymatic activity
(9% of wild type, at most). These results suggest that only a limited number of resistant viruses arise through mutations at
Glu 119 and Glu 227 under selective pressure from 4-guanidino-Neu5Ac2en and that the development of compounds which
interact with 227 Glu more strongly than does 4-guanidino-Neu5Ac2en may reduce the likelihood of drug-resistant viruses
still further. q 1997 Academic Press
INTRODUCTION in which the 4-hydroxyl group of Neu5Ac2en is replaced
by the guanidino group, which interacts with conserved
Neuraminidase (NA), which catalyzes the removal of Glu 119 and Glu 227 in the substrate binding pocket of
terminal sialic acid residues from oligosaccharide the enzyme. These interactions are thought to increase
chains, is one of the major surface glycoproteins of influ- the affinity of 4-guanidino-Neu5Ac2en with the NA mole-
enza virions (see Colman, 1989 for review). Because sia- cule, and indeed they are associated with inhibition of
lic acid is a critical component of influenza virus recep- influenza A and B viruses replication both in vitro and in
tors, the NA promotes the release of newly synthesized vivo (von Itzstein et al., 1993; Woods et al., 1993; Ryan et
virus from the cell surface and prevents virion aggrega- al., 1994; Gubareva et al., 1995; Ryan et al., 1995).
tion (Palese et al., 1974; Air and Laver, 1986). Influenza A and B viruses resistant to 4-guanidino-
A sialic acid analog, 2-deoxy-2,3-dehydro-N-acetyl- Neu5Ac2en have been isolated in tissue culture (Blick
neuraminic acid (Neu5Ac2en), inhibits influenza virus et al., 1995; Staschke et al., 1995; Gubareva et al., 1996;
replication in tissue culture but not in animals (Meindl Mckimm-Breschkin et al., 1996), but to date no resistant
et al., 1974; Palese and Schulman, 1977). Recently, von viruses have been isolated from clinical samples or in
Itzstein et al. (1993) used the three-dimensional structure animals (Hayden et al., 1996; Matsumoto et al., 1996).
of influenza virus NAs (Varghese et al., 1983) as a basis Among the resistant virues containing mutations in the
to synthesize an NA inhibitor, 4-guanidino-Neu5Ac2en, NA, most have had a Glu-to-Gly substitution at position
119, although viruses containing Ala or Asp at this posi-
tion have also been isolated. None of the resistant vi-1 Present address: Department of Pathobiological Sciences, School
ruses described thus far have had a mutation at positionof Veterinary Medicine, University of Wisconsin–Madison, 2015 Linden
Drive West, Madison, WI 53706. 227. Because the interaction between the guanidino
2 To whom correspondence and reprint requests should be ad- group of 4-guanidino-Neu5Ac2en and Glu 119 and Glu
dressed at present address: Department of Pathobiological Sciences,
227 makes this compound specific for the influenza virusSchool of Veterinary Medicine, University of Wisconsin–Madison, 2015
NA, we introduced mutations at amino acid residues 119Linden Drive West, Madison, WI 53706. Fax: (608) 265 5622. E-mail:
kawaokay@svm.vetmed.wisc.edu. and 227 and studied their effects on NA activity and
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sensitivity to 4-guanidino-Neu5Ac2en to elucidate the was sequenced to ensure that unwanted mutations were
not introduced. The expression plasmids for the wild-molecular mechanism of resistance to this recently de-
veloped antiviral agent. type and mutant NAs were transfected into 293T cells
using the lipofectamine reagent (Gibco BRL).
MATERIALS AND METHODS
Construction and expression of FLAG-N9NAViruses and cells
To introduce the FLAG epitope (Asp-Try-Lys-Asp-Asp-A reassortant virus, NWS-G70c, which contains the
Asp-Asp-Lys) (Prickett et al., 1989) in the NA stalk, wehemagglutinin (HA) gene of A/NWS/33 (H1N1) and the
used site-directed mutagenesis to replace nucleotidesNA gene of A/tern/Australia/G70c/75 (H11N9), was used
at positions 160 to 186 of the NA gene (amino acid resi-to clone the N9 NA gene. Human kidney 293T cells (Du-
dues 48 to 56 in the stalk) in pCAGGSN9NA with theBridge et al., 1987), used to transfect the NA gene, were
nucleotide sequence 5* GTCTACAAGGACGATGACGAC-maintained in Dulbecco’s modified Eagle’s medium con-
AAGCTT 3* (encoding the FLAG sequence plus Leu),taining 10% fetal calf serum.
resulting in pCRNAFLAG48. The N9NA gene fragment
containing the FLAG sequence, obtained by digestingCloning of the N9 NA gene
pCRNAFLAG48 with XhoI and MluNI, was used to re-
NWS-G70c RNA was isolated by treating viruses with place the corresponding region of the mutant NA gene in
proteinase K and sodium dodecyl sulfate followed by the pCAGGS plasmid. The mutant FLAG-N9NA plasmids
extraction with phenol:chloroform (1:1) (Bean et al., 1980). were transfected into 293T cells as described above.
cDNA was synthesized with AMV reverse transcriptase
(Life Sciences, Inc.) and a primer, 5*AGCAAAAGCAGG3*, Detection of NA expression
that is complementary to the 3* end of vRNA. It was then
amplified by the polymerase chain reaction (Saiki et al., At 48 h posttransfection, cells were treated with 0.02%
ethylenediaminetetraacetic acid (EDTA) in phosphate-1988) using the following primers: 5* CTCTTCGAGCAA-
AAGCAGGGTCAAGATG 3* and 5* TTATTAACCCTCAC buffed saline (PBS), pH 7.3, to detach them from plates.
Cell suspensions were passed through a 100-mm screenTAAAAGTAGATACAAGGGTCTTTTTTC 3* and PFU poly-
merase (Stratagene). PCR fragments of N9NA were and washed once with PBS. The NA expressed on the
cell surface was labeled with a mixture of the two mono-cloned into the pCRII vector (Invitrogen), which then was
designated pCRNA9-5. Seven nucleotides in the open clonal antibodies (mAbs) to the N9NA (NC-42 and NC-
46) and fluorescein isothiocyanate (FITC)-conjugatedreading frame of the cloned N9NA differed from the pub-
lished sequence of A/tern/Australia/G70C/75 (Air et al., goat anti-mouse immunoglobulin G antibodies (Boeh-
ringer Mannheim). For detection of intracellular NA bear-1985); however, all of the changes were silent.
ing the FLAG epitope (N9-FLAG), cells were fixed with
Site-directed mutagenesis 3.7% formaldehyde in PBS for 20 min at room temperature
and then treated with 1% Triton X-100 for 2 min. The NA-The mutant NA genes with changes in the codons for
FLAG was labeled with an anti-FLAG M2 mAb (not to beamino acid 119 or 227 (N2 numbering) were generated
confused with the M2 protein of influenza A virus) (East-with pCRNA9-5, degenerate oligonucleotides at the 119
man Kodak Co.). Fluorescence-activated cell sortingor 227 codon, and a commercial kit (Transformer site-
(FACS) to detect labeled cells was performed with a FAC-directed mutagenesis Kit, Clontech).
Scan instrument (Becton Dickinson).
Expression of N9 NAs
Assays for NA enzymatic activity
A plasmid expression vector, pCAGGS (Niwa et al.,
1991), was digested with EcoRI and BglII, and oligonucle- 293T cells transfected with plasmids were harvested by
treatment with 0.02% EDTA in PBS. After being washedotides containing recognition sites for EcoRI, SacI, ClaI,
NsiI, Asp718, SmaI, SphI, XhoI, NheI, and BglII were with PBS, the cells (approximately 5 1 106 cells) were
suspended in 250 ml of PBS containing 3.5 mM CaCl2 . Thecloned between the EcoRI and BglII sites to introduce
multiple cloning sites (pCAGGS/MCS). The N9NA gene, suspensions were then divided into 25-ml aliquots and
stored at 0807 until use. NA enzymatic activity was mea-obtained by digesting pCRNA9-5 with XhoI and BamHI,
was then subcloned into the XhoI and BglII sites of sured by the method of Warner and O’Brien (1979) using
2*-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid as apCAGGS/MCS (pCAGGSN9NA). The region of the mutant
NA genes in the pCRII vector that contained position 119 substrate. The procedure is almost identical to that pre-
viously described by Mitnaul et al. (1996) except that weand 227 codons was isolated by digesting with XhoI and
BglII and then used to replace the corresponding region used 0.5 mM substrate and 15 min of incubation. The
results are reported as the means of triplicate reactions.of the wild-type NA in pCAGGSN9NA. The resulting insert
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TABLE 1
Cell Surface Expression of Wild-Type and Mutant NA Moleculesa
Type of side % Cells with Type of side % Cells with
chain of amino surface chain of amino surface
acid substituted expression of acid substituted expression of
for 119Glu NA mutant the NA for 227Glu NA mutant the NA
Acidic Wild-type (119Glu) 83.6 Basic 227Arg 0.4
Basic 119Lys 86.9 227His 1.2
119His 83.8 Acidic 227Asp 72.1
Acidic 119Asp 71.5 Uncharged polar 227Asn 92.2
Uncharged polar 119Gln 83.6 227Gln 89.1
119Ser 83.7 227Tyr 0.4
119Thr 76.5 Nonpolar 227Gly 85.4
119Tyr 84.6 227Ala 83.7
Nonpolar 119Gly 78.5 227Val 0.8
119Ala 77.4 227Leu 0.7
119Val 82.4 227Pro 0.9
119Leu 80.5 227Phe 0.6
119Phe 91.3 227Cys 24.6
119Cys 68.2 Negative controlb 0.6
a In 293T cells transfected with the NA gene expression vector and probed with anti-NA mAbs. The data represent 10,000 cells analyzed by
FACS, as described in the legend to Fig. 1.
b 293T cells transfected with the pCAGGS/MCS vector.
Enzyme-linked immunosorbent assay dons for amino acid residues 119 and 227 by site-di-
rected mutagenesis. A total of 26 mutants (13 with
Cell suspensions, prepared as described above, were changes at position 119 and 13 at 227) were generated
diluted to 1:100 with PBS. One-hundred microliters of the (Table 1), with side chains that represented the basic,
diluted suspensions was then placed into the poly-L- acidic, uncharged polar, and nonpolar types.
lysine-coated wells of a 96-well microtiter plate. After
overnight absorption at 47, the cells were fixed with 3.7%
Expression of wild-type and mutant N9 NAs onformaldehyde–PBS for 10 min. Nonspecific binding of
mammalian cellsantibody was blocked with PBS containing 1% BSA. The
NA was detected with the two anti-N9 NA mAbs and Because a single mutation in the NA globular head
horseradish peroxidase-conjugated goat anti-mouse im- can render this molecule defective in intracellular trans-
munoglobulin G antibodies (Bio-Rad). 2,2*-Azino-di[3- port (Bos and Nayak, 1986), we assessed the expression
ethyl-benzthiazoline-6-sulfonic acid] was used as a sub- of mutant and wild-type NAs on 293T cells by FACS anal-
strate, and optical density was measured at 405 nm after ysis, using mAbs against N9NA as probes. After transfec-
1 h of color development. tion of the wild-type NA gene, the intact protein was
expressed on 83.6% of the cells (Fig. 1 and Table 1). The
Inhibition of NA by 4-guanidino-Neu5Ac2en majority of position 119 mutants were expressed on the
cell surface at a relatively high level, from 71.5 to 91.3%.Cell suspensions expressing the wild-type and mutant
Only 119Cys was expressed at a lower level (68.2%). ByNAs were diluted to obtain a 500 fluorescence count,
contrast, of 13 mutants with changes at position 227,with NA activity measured as described above. Diluted
only five (227Asp, 227Asn, 227Gln, 227Gly, and 227Ala)cell suspensions were preincubated with five different
were efficiently expressed on the cell surface (percent-concentrations of 4-guanidino-Neu5Ac2en (1004, 1002,
age of surface NA-positive cells, ranging from 72.1 to1001, 10, and 102 mM) for 30 min at room temperature. The
92.2%). 227Cys was also detected on the cell surface butenzymatic activity of treated cells was then measured as
at a reduced level (24.6%). The fluorescence intensitiesdescribed earlier in this section.
of cells expressing the wild-type and mutant NAs that
were expressed at a high efficiency were similar (Fig. 1),RESULTS
suggesting that equivalent amounts of NA were being
synthesized and transported to the cell surface.Using the NA gene of A/tern/Australia/G70c/75
(H11N9), whose three-dimensional structure is known To demonstrate that failure to detect NA surface ex-
pression by seven position 227 mutants was the result(Baker et al., 1987), we introduced mutations at the co-
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FIG. 1. Detection of NA proteins expressed on the surface of 293T cells. Expression plasmids for the wild-type and mutant NAs were transfected
into 293T cells, and mAbs to the N9NA, together with FITC-conjugated goat anti-mouse immunoglobulin G antibodies, were used to detect cell
surface NAs at 48 h posttransfection.
of defective intracellular transport, and not the failure of expression was at least 20% of the wild-type level. Using
different dilutions of cell suspensions expressing thegene expression, we replaced a portion of the NA stalk
with the FLAG epitope. This approach was taken be- wild-type NA, we first determined an optimal experimen-
tal condition under which reaction velocity is in a linearcause none of 33 mAbs to the N9NA reacted with the
denatured wild-type N9NA, and a monospecific rabbit range (data not shown). On the basis of this result, we
chose an incubation time of 15 min and 100-fold dilutionsantiserum to the NA of A/Duck/Germany/73 (H2N9) did
not react with the G70c N9NA. Wild-type N9NA bearing of cell suspensions expressing the wild-type or mutant
NAs for all subsequent experiments. The NA activity ofthe FLAG epitope (FLAG-N9NA) in the stalk showed the
same level of NA cell surface expression and enzymatic the mutants relative to the wild-type (Table 2, right col-
umn) was determined by standardizing the enzymaticactivity as the wild-type NA without the FLAG epitope
(data not shown). By contrast, when the FLAG epitope activities of the cell suspension (Table 2, left column)
based on the relative amount of NA expressed on thewas inserted into the NA stalk of the seven mutants, it
was detected only in cells that had been treated with cell surface (Table 2, middle column). With the exception
of 119Gln, mutations at either position 119 or positionTriton X-100 (data not shown), confirming the presumed
failure of intracellular protein transport. Thus, mutations 227 reduced NA enzymatic activity. The majority of 227
mutants had less than 10% of the wild-type activity.at position 227 have a much more pronounced effect on
NA cell surface expression than do those at position 119.
Sensitivity of NA mutants to 4-guanidino-Neu5Ac2enEnzymatic activity of expressed NA
We next examined the effect of mutations at position Six NA mutants—119Gln, 119Thr, 119Gly, 119Ala,
119Val, and 119Leu—all retaining more than 20% of the119 or 227 on the activity of NAs whose cell surface
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TABLE 2 bearing mutations other than Gly at position 119 (Gubar-
eva et al., 1996). How, then, does one explain the predom-Enzymatic Activity of Mutant NAs
inance of Glu-to-Gly changes in the mutant NAs of resis-
NA activity Amount of NA Relative tant viruses selected in vitro (Blick et al., 1995; Staschke
NA of cell protein on cell enzymatic et al., 1995; Gubareva et al., 1996)? A single mutation in
mutant suspension (%)a surface (%)b activity (%)c the NA 119Glu codon (GAA) of the NWS-G70c virus,
which was used as a source of the NA gene in this studyWild-type 100 100 100
and for the isolation of resistant viruses by others (Blick119Lys — d 54.7 —
119His — 47.0 — et al., 1995; Staschke et al., 1995), can result in nine
119Asp 3.0 42.2 7.1 different codons, including a stop codon. Among the
119Gln 136.7 97.3 140.5 eight possible mutations, four [Gln (CAA), Val (GTA), Gly
119Ser 6.2 71.4 8.7
(GGA), and Ala (GCA)] generate tolerable reductions in119Thr 26.2 43.2 60.7
NA activity (Table 2). Of these, we would predict that both119Tyr 0.2 67.0 0.3
119Gly 12.3 42.3 29.1 119Val and 119Ala, which show at least the same or
119Ala 17.1 32.3 53.0 higher NA activity than 119Gln, would be as resistant to
119Val 24.3 66.9 36.3
4-guanidino-Neu5Ac2en as the latter mutant. The 119Gly119Leu 53.8 76.8 70.1
mutation may have been more frequent than others be-119Phe — 74.5 —
119Cys 3.1 22.5 13.8 cause it represents a transition change, GAA to GGA,
227Asp 1.6 63.1 2.5
227Asn — 84.0 —
227Gln — 76.0 —
227Gly — 58.9 —
227Ala — 45.9 —
227Cys — 0 —
a Reported as the percentage of wild-type NA activity (mean of tripli-
cate reactions).
b Cell surface NA was measured by ELISA using NA-specific mAbs
and quantified relative to the wild-type control, as described under
Materials and Methods.
c The values were calculated as relative enzymatic activities, com-
pared with the wild-type protein, after standardizaiton of NA expression
on the cell surface.
d Less than the value of a negative control (expression vector only).
wild-type NA activity, were tested for their sensitivity to 4-
guanidino-Neu5Ac2en, using cell suspensions with equiv-
alent levels of enzymatic activity. After 30 min of preincuba-
tion, each of the mutants showed reduced sensitivity to
the antiviral compound, with IC50 values ranging from 7-
to 1412-fold higher than the result for the wild-type NA
(Fig. 2 and Table 3). Thus, a variety of amino acid changes
at position 119, not solely Glu r Gly, Glu r Ala or Glu r
Asp, can generate resistance to 4-guanidino-Neu5Ac2en.
DISCUSSION
In this study, we introduced mutations at amino acid
residue 119 or 227 of the influenza virus NA and studied
their effects on the protein’s enzymatic activity and sensi-
FIG. 2. Inhibition of position 119 NA mutants by 4-guanidino-Neu5A-tivity to 4-guanidino-Neu5Ac2en. In most instances, the
c2en. Mutant NAs with identical activities (500 fluorescence count,mutations resulted in lower NA activity relative to the
assayed as described under Materials and Methods) were preincu-wild-type NA. Six mutants (119Gln, 119Gly, 119Ala,
bated with different concentrations of 4-guanidino-Neu5Ac2en at room
119Thr, 119Leu, and 119Val) retained at least 20% of their temperature for 30 min. NA activity was then measured after 15 min
NA activity and were resistant to 4-guanidino-Neu5A- of incubation with 4MU-NANA. The results are the means of triplicate
reactions.c2en, supporting previous reports of resistant viruses
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TABLE 3 reduced NA activity had HA mutations. Isolation of a virus
resistant to 4-guanidino-Neu5Ac2en with mutations inInhibition of Residue 119 Mutants by 4-Guanidino-Neu5Ac2en
the HA but not in the NA (Mckimm-Breschkin et al., 1996)
NA mutant IC50 (mM)a further supports this notion. Whether viruses with re-
duced receptor affinity replicate as efficiently as wild-
Wild-type 6.9 1 1004 type viruses in vivo is unknown. Such viruses may be
119Gln 4.8 1 1003
attenuated due to the reduced efficiency of virus entry119Gly 9.8 1 1001
to cells.119Ala 2.4 1 1001
119Thr 1.5 1 1001 Amino acid residues 119 and 227 are located in the
119Leu 1.2 1 1001 active site of the influenza virus NA and are well conserved
119Val 1 1 1001 among influenza A and B viruses (Colman et al., 1983;
Bossart-Whitaker et al., 1993), suggesting their biologicala Determined from data presented in Fig. 2.
importance. The findings we report substantiate this notion
and confirm the data of Lentz and Air (1986) and Lentz et
al. (1987) showing that alteration of conserved amino acid
residues in the active site of the A/Tokyo/3/67 (N2) NAwhereas 119Val (GTA) and 119Ala (GCA) are transver-
sions (Collins and Jukes, 1994). This possibility also ap- either abolishes or reduces enzymatic activity. The reduced
enzymatic activity of the mutant NAs generated in our studyplies to the GAG codon of 119Glu, which is found in other
influenza virus NAs (Fields et al., 1981; Hiti and Nayak, may partly stem from their instability, as reported for 119Gly
mutant by Mckimm-Breschkin et al. (1996). It should be1982; Saito et al., 1993). The 119Gln transition mutant
had the highest NA activity among all NAs tested includ- emphasized, however, that the extent of the effect depends
on the position of the amino acid substitution in the NAing the wild type. However, it showed only marginal resis-
tance to 4-guanidino-Neu5Ac2en (Fig. 2), which may ex- molecule: that is, alteration of the 227 residue yields a much
greater effect than does modification at the 119 position.plain the lack of isolation of resistant viruses with this
mutation in tissue culture. Varghese et al. (1995) have shown that the principal
hydrogen bonding interactions between the guanidinoThe relative scarcity of 119Val (GTA) and 119Ala (GCA)
mutations in tissue culture-isolated 4-guanidino-Neu5A- group of 4-guanidino-Neu5Ac2en and the NA active site
involve residues 178, 227, and 151. The guanidino groupc2en mutants could reflect unknown effects on NA func-
tion other than sialidase activity, thus restricting the ap- also interacts with 119Glu but mainly electrostatically,
as the geometry of the guanidino group precludes thepearance of resistant viruses. An amino acid change at
position 119 may also depend on NAs that differ in other formation of a hydrogen bond for this interaction. These
findings support the relatively low levels of resistanceamino acid residues, because 119Ala and 119Asp mu-
tants have been isolated only with A/turkey/Minnesota/ conferred by mutations at position 119 (20- to 40-fold for
E119G and E119A) when Ki values are compared (Blick833/80 (H4N2) virus (Gubareva et al., 1996). 119Thr or
119Leu mutants have not been isolated, probably be- et al., 1995; Gubareva et al., 1996). The position 227 mu-
tants that we tested were either defective in intracellularcause they require two mutations in a single codon. An-
other factor that could contribute to the emergence of 4- transport or had considerably reduced NA activity.
These observations suggest that a compound as ac-guanidino-Neu5Ac2en-resistant viruses is the stability of
NA proteins. Mckimm-Breschkin et al. (1996) showed that tive as 4-guanidino-Neu5Ac2en, independent of the inter-
action with 119 residue, might reduce the likelihood ofthe 119Gly mutant has the same specific activity as the
wild-type protein, but is unstable. Thus, we conclude that the emergence of drug-resistant variants, since 227 mu-
tations enabling the NA to escape the drug’s effect aremultiple factors are responsible for the generation of vi-
ruses resistant to this drug. probably lethal (Tables 1 and 2). The three-dimensional
structure of a complex of N9NA with Neu5Ac2en revealsWe would emphasize that our findings should be inter-
preted in the context of possible cooperative mutations. that 227Glu is located in the active site but does not
directly interact with the substrate (Bossart-Whitaker etSome viruses resistant to 4-guanidino-Neu5Ac2en have
been shown to contain mutations in the HA (Gubareva al., 1993). Some amino acid residues including 227Glu in
the NA stabilize the active site by a network of hydrogenet al., 1996; Mckimm-Breschkin et al., 1996). This raises
the possibility that viruses with substantially reduced NA bonds. Hence, compounds that interact with amino acids
stabilizing the active site are likely to be effective inhibi-activity could still develop resistance to 4-guanidino-Neu-
5Ac2en if the HA mutation reduces receptor affinity suffi- tors of NA activity.
cient to permit efficient release of virus from the host cell
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